Oncopeptides AB (publ) (FRA:OND)
0.1470
-0.0002 (-0.14%)
At close: Mar 6, 2026
Oncopeptides AB Balance Sheet
Financials in millions SEK. Fiscal year is January - December.
Millions SEK. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 82.26 | 178.54 | 173.41 | 344.52 | 362.19 |
Short-Term Investments | - | - | 0.03 | 0.35 | 2.11 |
Cash & Short-Term Investments | 82.26 | 178.54 | 173.44 | 344.86 | 364.3 |
Cash Growth | -53.93% | 2.94% | -49.71% | -5.33% | -57.27% |
Accounts Receivable | 26.66 | 7.29 | 2.19 | 0.67 | 11.87 |
Other Receivables | - | 6.24 | 15.68 | 16.25 | 24.01 |
Receivables | 26.66 | 13.53 | 17.87 | 16.92 | 35.89 |
Inventory | 8.24 | 4.37 | 2.43 | - | - |
Prepaid Expenses | - | 6.19 | 5.43 | 1.71 | 7.42 |
Other Current Assets | - | 9.96 | 3.73 | 0.54 | 4.76 |
Total Current Assets | 117.16 | 217.08 | 202.9 | 364.03 | 412.37 |
Property, Plant & Equipment | 17.68 | 27.11 | 34.63 | 20.44 | 24.74 |
Other Intangible Assets | - | - | - | - | 1.41 |
Other Long-Term Assets | - | -0 | 0.85 | 0.85 | 0.85 |
Total Assets | 134.84 | 244.19 | 238.38 | 385.32 | 439.38 |
Accounts Payable | 0.7 | 18.17 | 15.03 | 28.22 | 35.7 |
Accrued Expenses | - | 15.12 | 20.38 | 17.24 | 36.61 |
Current Portion of Leases | - | 7.27 | 5.13 | 6 | 10.99 |
Current Income Taxes Payable | - | 1.73 | 0.58 | 0.3 | 0.05 |
Current Unearned Revenue | - | 0.07 | 0.5 | - | - |
Other Current Liabilities | 43.8 | 4.66 | 3.32 | 33.91 | 141.94 |
Total Current Liabilities | 44.5 | 51.36 | 44.93 | 85.67 | 225.29 |
Long-Term Debt | 126.68 | 121.89 | 106.49 | - | - |
Long-Term Leases | 22.55 | 12.55 | 19.67 | - | 3.21 |
Other Long-Term Liabilities | - | 4.11 | 10.51 | 5.36 | 0.01 |
Total Liabilities | 193.73 | 189.91 | 181.6 | 91.03 | 228.51 |
Common Stock | 30.3 | 23.91 | 10.51 | 10.48 | 8.37 |
Additional Paid-In Capital | - | 5,684 | 5,414 | 5,403 | 4,982 |
Retained Earnings | - | -5,651 | -5,366 | -5,116 | -4,778 |
Comprehensive Income & Other | -89.19 | -2.84 | -2.2 | -2.3 | -0.92 |
Shareholders' Equity | -58.89 | 54.29 | 56.78 | 294.29 | 210.87 |
Total Liabilities & Equity | 134.84 | 244.19 | 238.38 | 385.32 | 439.38 |
Total Debt | 149.23 | 141.72 | 131.29 | 6 | 14.19 |
Net Cash (Debt) | -66.97 | 36.82 | 42.15 | 338.86 | 350.11 |
Net Cash Growth | - | -12.65% | -87.56% | -3.21% | -57.98% |
Net Cash Per Share | -0.30 | 0.22 | 0.47 | 4.12 | 4.65 |
Filing Date Shares Outstanding | 272.71 | 215.19 | 94.6 | 94.31 | 75.29 |
Total Common Shares Outstanding | 272.71 | 215.19 | 94.6 | 94.31 | 75.29 |
Working Capital | 72.66 | 165.73 | 157.97 | 278.36 | 187.08 |
Book Value Per Share | -0.22 | 0.25 | 0.60 | 3.12 | 2.80 |
Tangible Book Value | -58.89 | 54.29 | 56.78 | 294.29 | 209.46 |
Tangible Book Value Per Share | -0.22 | 0.25 | 0.60 | 3.12 | 2.78 |
Machinery | - | 16.46 | 16.1 | 15.99 | 14.42 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.